Accunea
Founded 2017 · 8 employees on LinkedIn · 1 known investors
Accunea develops organ condition monitoring technology that tracks biomarkers of kidney function and metabolism before and after transplantation, providing clinicians with continuous point-of-care data and AI-driven trend analysis. It serves transplant centres and clinicians to assess organ viability and support patient recovery, and integrates with hospital EPR systems.
Investors · 1
Companies House · registry record
View on Companies House ↗Confirmation statement overdue
- Registered name
- ACCUNEA LTD.
- Company number
- 10661414
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 9 Mar 2017
- Registered office
- 25 Church Street, Kidderminster, DY10 2AW
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 5 Dec 2024 · next due 19 Dec 2025
Current officers · 5
- Warren Robert Delo — director, appointed 20 Apr 2023
- Dylan Evans — director, appointed 19 May 2023
- Robert Michael Learney — director, appointed 9 Mar 2017
- Amita Nand — director, appointed 15 Oct 2023
- John Leslie Sulley — director, appointed 18 Mar 2024
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Accunea do?
- Accunea develops organ condition monitoring technology that tracks biomarkers of kidney function and metabolism before and after transplantation, providing clinicians with continuous point-of-care data and AI-driven trend analysis. It serves transplant centres and clinicians to assess organ viability and support patient recovery, and integrates with hospital EPR systems.
- Who are Accunea's investors?
- Accunea's investors include Innvotec Ltd..